Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Autor: Kennedy, Nicholas A, Goodhand, James R, Bewshea, Claire, Nice, Rachel, Chee, Desmond, Lin, Simeng, Chanchlani, Neil, Butterworth, Jeffrey, Cooney, Rachel, Croft, Nicholas M, Hart, Ailsa L, Irving, Peter M, Kok, Klaartje B, Lamb, Christopher A, Limdi, Jimmy K, Macdonald, Jonathan, McGovern, Dermot Pb, Mehta, Shameer J, Murray, Charles D, Patel, Kamal V, Pollok, Richard Cg, Raine, Timothy, Russell, Richard K, Selinger, Christian P, Smith, Philip J, Bowden, Jack, McDonald, Timothy J, Lees, Charlie W, Sebastian, Shaji, Powell, Nicholas, Ahmad, Tariq, Contributors To The CLARITY IBD Study

Publikováno v: 2021, ' Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab ', Gut, vol. 70, no. 5, pp. 865-875 . https://doi.org/10.1136/gutjnl-2021-324388
Gut

ObjectiveAntitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6e01dd054652cb9b8697520d2d594a
https://hdl.handle.net/20.500.11820/1bfd49d0-2ff9-4251-9b80-3c64409dface